CAJ | 학술논문

目的：探讨恩度联合FOLFOX4方案对中晚期胃癌的临床疗效及安全性。方法中晚期胃癌53例，随机分为观察组31例，对照组22例。对照组采用FOLFOX4方案，观察组在对照组基础上加用重组人血管内皮抑制素注射液；比较两组临床疗效、血清肿瘤标志物变化水平以及不良反应发生情况。结果观察组有效率显著高于对照组，两组间比较差异具有统计学意义（字2=13.913，P约0.05）；与对照组比较，观察组血清CEA、CA50、CA125、CA153、CA199水平显著降低（P约0.05）。两组间不良反应发生率差异无统计学意义（P跃0.05）。结论恩度联合FOLFOX4方案治疗中晚期胃癌有效，不良反应均可耐受，是一种安全有效的治疗方案。
목적：탐토은도연합FOLFOX4방안대중만기위암적림상료효급안전성。방법중만기위암53례，수궤분위관찰조31례，대조조22례。대조조채용FOLFOX4방안，관찰조재대조조기출상가용중조인혈관내피억제소주사액；비교량조림상료효、혈청종류표지물변화수평이급불량반응발생정황。결과관찰조유효솔현저고우대조조，량조간비교차이구유통계학의의（자2=13.913，P약0.05）；여대조조비교，관찰조혈청CEA、CA50、CA125、CA153、CA199수평현저강저（P약0.05）。량조간불량반응발생솔차이무통계학의의（P약0.05）。결론은도연합FOLFOX4방안치료중만기위암유효，불량반응균가내수，시일충안전유효적치료방안。
Objective To investigate the clinical efficacy and safety of Endostar combined with FOLFOX4 regi-men for advanced gastric cancer. Methods Fifty-three cases of advanced gastric cancer treated in our hospital were randomly assigned to receive recombinant human endostatin injection(Endostar) plus FOLFOX4 regimen(n=31) or FOLFOX4 regimen monotherapy(n=22). The clinical efficacy, levels of serum tumor marker, and the incidence of adverse events were compared between two groups. Results The effective rate in patients receiving Endostar plus FOLFOX 4 regimen was significantly higher than that in patients receiving FOLFOX4 regimen monotherapy(58.06%vs 31.82%, x2=13.913, P<0.05).The levels of serum CEA, CA50, CA125, CA153, and CA199 were lower in En dostar-treated patients as compared with those treated by FOLFOX4 regimen monotherapy(P<0.05). No significant difference in adverse events was found between two groups(P>0.05). Conclusion Endostar combined with FOL-FOX4 regimen can effectively reduce progression of advanced gastric cancer and can be well tolerated by patients.